Nanosphere will raise up to $30M; Bionic suits could help the disabled and elderly;

@FierceMedDev: Here's our latest FierceDiagnostics, with news on concussion biomarkers, autism tests and more. Newsletter | Follow @FierceMedDev

@MarkHFierce: A European VC firm is raising $ for a new fund that will target, in part, Dx and device companies. Story | Follow @MarkHFierce

@MichaelGFierce: NASA tech makes space-age microcapsules for cancer drug delivery. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Good news for chocolate lovers: Bacteria in the gut can eat up cocoa and turn it into compounds that help the heart. Article | Follow @EmilyWFierce

> Nanosphere ($NSPH), a molecular diagnostics developer, will sell up to $30 million of its common stock to shareholder Aspire Capital. Release

> Medical device makers are warning that tighter regulations in Europe could push their development work away from the region and to countries such as China. Story

> California's Aurora Spine said a surgeon in Poland has performed the first surgical procedure there involving its new spinal fusion implant. Release

> Trovagene will work with the Catholic Health Initiatives Center for Translational Research to test the usefulness of the company's urine-based cell-free DNA cancer monitoring tests in clinical practice. Release

> A number of new companies in the U.S., Europe and Japan are developing bionic suits that could, in part, help aging and disabled patients care for themselves. Story

Biotech News

@FierceBiotech: Novo touts a PhIII hemophilia win as it chases Biogen, Bayer. Story | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers partner Alder Bio looking for $115M IPO haul - clazakizumab and migraine drug ALD403. More | Follow @JohnCFierce

@DamianFierce: Proteon sets out on its own after Novartis waves off a $550M deal. News | Follow @DamianFierce

@GalenMoore: Exact Sciences' at-home test for colon cancer is nearly as effective as a colonoscopy. Read more at Bloomberg | Follow @GalenMoore

> The FDA vs. the flash mob: Hard questions as parents demand unproven drugs. More

> A renal cancer study fails and stock plunges, but Bionomics stays upbeat. Story

Pharma News

@FiercePharma: Statins and muscle aches are unrelated. Story | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Article | Follow @TracyStaton

@EricPFierce: New purification plant is part of Novo Nordisk 's $3.7B R&D push. News | Follow @EricPFierce

> Tamiflu study funded by Roche shows lives saved in pandemic. More

> Roche breast cancer drugs Perjeta, Kadcyla are built for speed, report finds. Item

> Medivation, Astellas ask FDA to approve Xtandi for pre-chemo prostate cancer use. Piece

Drug Delivery News

> MedImmune inks licensing deal with Bioasis for brain delivery platform. News

> GenSpera enrolls brain cancer mid-stage trial with 'grenade' delivery. Story

> NASA tech makes space-age microcapsules for cancer drug delivery. Story

> Harvard scientists fold DNA to make cages for drug delivery. Article

> CeloNova wins a U.S. exemption trial for its nano-coated stent. News

> Oral drugs derived from snail venom could offer less invasive pain management. Brief

Diagnostics News

> Waters Corp. will help develop a blood-based biomarker test to predict the risk of premature birth. Story

> SynapDx and the Broad Institute link to use next-gen sequencing for better autism tests. News

> Quanterix diagnostic spotted a key concussion biomarker in blood. Article

> Is diagnostics maker Corgenix looking to sell itself? Story

> For 2014, Trovagene plots multiple ways to expand the reach of its Dx cancer tech. Story

> Federal funding drops are forcing layoffs at the Broad Institute's genome sequencing arm. Brief

Pharma Marketing News

> They're no Coca-Cola, but top biopharma brands Pfizer, Biogen and Merck still worth billions. Report

> Roche's Perjeta proves a fast fave with cancer docs, but Kadcyla's a speed racer. Story

> McKinsey's four drug launch flavors: Good, bad, ugly and misguided. Story

> Pfizer's impressive Prevnar data isn't enough to win billions in adult sales. Analysis

> For once, the FDA writes up pharma for a simple Facebook violation. News

> Probe finds Novartis not guilty of 'undue influence' at Canadian university eye clinic. Brief

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.